# Lactococcus lactis L1A

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactococcus-lactis-l1a
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. lactis L1A, Lactococcus lactis strain L1A, L1A strain, Lactococcus lactis L1A probiotic strain

## Overview

Lactococcus lactis L1A is a lactic acid-producing bacterial strain studied for its potential cholesterol-modulating and [antimicrobial](/ingredients/condition/immune-support) properties, primarily through production of bacteriocins and bile salt hydrolase (BSH) activity. Its mechanisms parallel other L. lactis strains but strain-specific human clinical data for L1A remains limited.

## Health Benefits

• Potential cholesterol reduction - animal studies show various L. lactis strains may lower cholesterol, though human data for L1A is lacking
• Possible wound healing support - one L. lactis strain showed benefits in oral mucosal wound models, but not specifically L1A
• [Antimicrobial](/ingredients/condition/immune-support) activity - in vitro studies demonstrate antimicrobial properties for some L. lactis strains
• Acid and bile tolerance - laboratory tests show [probiotic](/ingredients/condition/gut-health) potential, but no human trials for L1A
• General probiotic properties - based on genus characteristics, not strain-specific evidence

## Mechanism of Action

Lactococcus lactis L1A may lower cholesterol through bile salt hydrolase (BSH) enzymes that deconjugate bile acids, reducing their reabsorption in the gut and forcing the liver to synthesize new bile acids from circulating cholesterol. The strain produces bacteriocins — ribosomally synthesized [antimicrobial](/ingredients/condition/immune-support) peptides — that disrupt competing bacterial cell membranes by forming pores, inhibiting pathogen growth. Additionally, L. lactis strains broadly stimulate intestinal epithelial tight junction proteins such as occludin and claudin, potentially supporting mucosal barrier integrity via [NF-κB](/ingredients/condition/inflammation) pathway modulation.

## Clinical Summary

Human clinical trial data specific to the L1A strain is currently absent from the published literature, making efficacy claims reliant on extrapolation from related L. lactis strains. Animal studies using various L. lactis strains have demonstrated total cholesterol reductions of approximately 10–20% in rodent models, though direct applicability to L1A is unconfirmed. In vitro [antimicrobial](/ingredients/condition/immune-support) studies show L. lactis strains inhibit pathogens including Listeria monocytogenes and Staphylococcus aureus via bacteriocin production, but strain-specific MIC values for L1A are not well-characterized. Overall, the evidence base is preliminary and preclinical; robust randomized controlled trials in humans are needed before therapeutic claims can be substantiated.

## Nutritional Profile

Lactococcus lactis L1A is a probiotic microorganism; its nutritional contribution as a supplement is derived from its cellular components and metabolic byproducts rather than classical macronutrient content. Protein content: bacterial cells are approximately 50-60% protein by dry weight, comprising primarily structural and enzymatic proteins including cell wall-associated proteins and surface-layer proteins; exact concentration in finished product varies by CFU count and formulation. Carbohydrates: cell wall peptidoglycan and polysaccharides account for roughly 10-20% of dry cell mass; L. lactis produces exopolysaccharides (EPS) which contribute [prebiotic](/ingredients/condition/gut-health)-like bioactive activity. Lipids: membrane lipids constitute approximately 10-15% of dry weight, predominantly phospholipids and glycolipids with no significant omega-3/6 content. Bioactive compounds: produces bacteriocins (nisin-like lantibiotics reported for some L. lactis strains, [antimicrobial](/ingredients/condition/immune-support) peptides), lactic acid as primary fermentation metabolite (contributes to gut acidification), and diacetyl in minor quantities. Vitamins: L. lactis strains are documented producers of riboflavin (B2) at approximately 0.1-1.0 µg/mL in culture; some strains produce folate (B9) at 10-100 ng/mL culture levels; B12 production is not characteristic of L. lactis. Minerals: cellular content includes intracellular magnesium (~50-100 mM intracellular), potassium, and phosphorus bound in nucleic acids and ATP; dietary contribution at typical probiotic doses (10^8-10^10 CFU) is nutritionally negligible for minerals. Bioavailability note: nutritional contributions from cellular components are minimal at standard probiotic doses; primary value is functional/bioactive rather than nutritional. Specific compositional data for the L1A strain designation is not independently published; values extrapolated from L. lactis species-level literature.

## Dosage & Preparation

No clinically studied dosage ranges are available for Lactococcus lactis L1A in humans. Animal studies with other L. lactis strains have used various CFU counts, but these cannot be extrapolated to human dosing recommendations. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactococcus lactis is generally recognized as safe (GRAS) by the FDA and has a long history of use in food fermentation, suggesting a favorable safety profile for healthy adults. Immunocompromised individuals, those with short bowel syndrome, or patients with central venous catheters should exercise caution with any live bacterial supplement, as rare cases of bacteremia have been associated with lactobacillales-family organisms. No well-documented drug interactions specific to L1A exist, though concurrent use with broad-spectrum antibiotics may reduce bacterial viability and efficacy. Pregnancy and breastfeeding safety has not been formally studied for L1A specifically; consultation with a healthcare provider is recommended before use in these populations.

## Scientific Research

No human clinical trials or meta-analyses are available for the specific L1A strain designation. Available research consists primarily of in vitro characterization and animal model studies for other L. lactis strains, making evidence-based claims about L1A specifically not possible without proper strain identification and human trial data.

## Historical & Cultural Context

No traditional or historical medicinal use is documented for Lactococcus lactis L1A specifically. L. lactis as a species is primarily known for its use in dairy fermentation rather than traditional medicine applications.

## Synergistic Combinations

Insufficient data to recommend synergistic combinations

## Frequently Asked Questions

### What is Lactococcus lactis L1A used for?

Lactococcus lactis L1A is primarily investigated for potential cholesterol reduction, antimicrobial activity, and mucosal wound healing support based on research into related L. lactis strains. It produces bacteriocins and may express bile salt hydrolase activity, which are the main proposed mechanisms. However, no published human trials specific to the L1A designation currently confirm these effects in clinical settings.

### Can Lactococcus lactis L1A lower cholesterol?

Animal studies using various L. lactis strains have shown total cholesterol reductions of roughly 10–20% in rodent models, likely through bile salt hydrolase (BSH)-mediated deconjugation of bile acids. This forces hepatic conversion of cholesterol into new bile acids, effectively reducing serum cholesterol levels. No human trials have tested L1A specifically for cholesterol reduction, so this benefit cannot yet be confirmed for this strain.

### What are the side effects of Lactococcus lactis L1A?

For healthy adults, L. lactis strains are generally well-tolerated with mild transient gastrointestinal effects such as bloating or gas being the most commonly reported issues with probiotic supplementation broadly. Serious adverse events are rare but include a theoretical risk of bacteremia in immunocompromised individuals or those with compromised gut barriers. No L1A-specific adverse event data is published, so risk profiles are inferred from the broader L. lactis species safety record.

### How does Lactococcus lactis L1A fight bacteria?

L. lactis L1A produces bacteriocins — small, ribosomally synthesized antimicrobial peptides — that target the cell membranes of competing or pathogenic bacteria by forming pores, leading to ion leakage and cell death. The species broadly inhibits pathogens such as Listeria monocytogenes and Staphylococcus aureus in vitro through this mechanism. Strain-specific minimum inhibitory concentration (MIC) data for L1A against particular pathogens has not been clearly published in accessible literature.

### Is Lactococcus lactis L1A the same as other L. lactis probiotic strains?

No — while L1A shares species-level characteristics with other Lactococcus lactis strains such as nisin-producing strains or IL1403, each strain designation indicates distinct genetic and functional differences that can affect bacteriocin output, BSH activity, adhesion properties, and clinical efficacy. Probiotic benefits are highly strain-specific, meaning results observed with one L. lactis strain cannot be reliably extrapolated to L1A without direct testing. Consumers should look for products citing L1A-specific research rather than general L. lactis data.

### Is Lactococcus lactis L1A safe during pregnancy and breastfeeding?

Lactococcus lactis is a food-grade, non-pathogenic bacterium with a long history of safe use in fermented dairy products, suggesting general safety during pregnancy and breastfeeding. However, specific safety data for the L1A strain during these periods is limited, and pregnant or breastfeeding women should consult their healthcare provider before supplementing. Most probiotic strains are considered safe in these populations, but individual medical history and product quality matter.

### How much Lactococcus lactis L1A should I take, and how often?

Typical probiotic dosing ranges from 1–10 billion CFU (colony-forming units) daily, though specific dosing guidelines for L1A strain have not been standardized in clinical trials. The optimal dose may depend on the intended health benefit, product formulation, and individual factors such as age and digestive health. It is best to follow the manufacturer's dosing instructions on the supplement label or consult a healthcare provider for personalized guidance.

### What does current clinical research show about Lactococcus lactis L1A's effectiveness?

While Lactococcus lactis as a species has been studied for potential cholesterol and immune benefits, clinical human trials specifically on the L1A strain are limited. Most available evidence comes from in vitro (laboratory) and animal studies, which show promise but do not directly confirm efficacy in humans. Stronger human clinical trials would be needed to definitively establish L1A's effectiveness for any health claim.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*